TW200505828A - Substituted ureas and carbamates useful in the treatment of alzheimer's disease - Google Patents

Substituted ureas and carbamates useful in the treatment of alzheimer's disease

Info

Publication number
TW200505828A
TW200505828A TW092133639A TW92133639A TW200505828A TW 200505828 A TW200505828 A TW 200505828A TW 092133639 A TW092133639 A TW 092133639A TW 92133639 A TW92133639 A TW 92133639A TW 200505828 A TW200505828 A TW 200505828A
Authority
TW
Taiwan
Prior art keywords
disease
treatment
alzheimer
useful
substituted ureas
Prior art date
Application number
TW092133639A
Other languages
English (en)
Inventor
Shon R Pulley
John A Tucker
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32469374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200505828(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of TW200505828A publication Critical patent/TW200505828A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/52—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
TW092133639A 2002-11-27 2003-11-27 Substituted ureas and carbamates useful in the treatment of alzheimer's disease TW200505828A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42976902P 2002-11-27 2002-11-27

Publications (1)

Publication Number Publication Date
TW200505828A true TW200505828A (en) 2005-02-16

Family

ID=32469374

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092133639A TW200505828A (en) 2002-11-27 2003-11-27 Substituted ureas and carbamates useful in the treatment of alzheimer's disease

Country Status (14)

Country Link
US (2) US7351738B2 (zh)
EP (1) EP1565428A1 (zh)
JP (1) JP2006508166A (zh)
AR (1) AR043062A1 (zh)
AU (1) AU2003293155A1 (zh)
BR (1) BR0316629A (zh)
CA (1) CA2507484A1 (zh)
DO (1) DOP2003000765A (zh)
MX (1) MXPA05005649A (zh)
PA (1) PA8589701A1 (zh)
PE (1) PE20040762A1 (zh)
TW (1) TW200505828A (zh)
UY (1) UY28101A1 (zh)
WO (1) WO2004050609A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007522129A (ja) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
US20050261273A1 (en) * 2004-03-09 2005-11-24 Varghese John Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2556826A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087751A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2572775A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
JP2008505930A (ja) 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US20080207527A1 (en) * 2004-09-17 2008-08-28 Comentis, Inc. Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
EP2457901A1 (en) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
AU2006235344B2 (en) * 2005-04-08 2012-07-26 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
WO2007019111A2 (en) * 2005-08-03 2007-02-15 Merck & Co., Inc. Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007029587A1 (ja) * 2005-09-05 2007-03-15 Dainippon Sumitomo Pharma Co., Ltd. βセクレターゼ阻害剤
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
EP1971598A1 (en) * 2005-11-21 2008-09-24 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2008137954A2 (en) * 2007-05-07 2008-11-13 Environmental Packaging Technologies Limited Universal shipping container
US8173810B2 (en) 2007-05-25 2012-05-08 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009015369A2 (en) * 2007-07-26 2009-01-29 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
JP2011518188A (ja) * 2008-04-18 2011-06-23 ユニバーシティ オブ コネチカット リソソーム調節のための化合物および使用方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6133152A (ja) * 1984-06-22 1986-02-17 アボツト　ラボラトリ−ズ リ−ニン阻害化合物
EP0190891A3 (en) * 1985-01-31 1988-04-20 Kissei Pharmaceutical Co. Ltd. Novel amino acid derivatives
US4665055A (en) * 1985-06-17 1987-05-12 Merck & Co., Inc. Peptide renin inhibitors
US5175281A (en) 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
CA1297631C (en) * 1985-12-23 1992-03-17 Sesha I. Natarajan Ureido renin inhibitors
US4864017A (en) 1986-09-05 1989-09-05 The Upjohn Company Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
EP0813868B1 (en) * 1990-11-19 2005-06-01 Monsanto Company Retroviral protease inhibitors
DE69233468T3 (de) 1991-01-21 2011-05-05 Elan Pharmaceuticals, Inc., San Francisco Prüfung und modell für alzheimers-krankheit
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993001166A1 (en) * 1991-07-02 1993-01-21 Sandoz Ltd. 4-amino-3-hydroxycarboxylic acid derivatives
WO1993014200A1 (en) 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
DK0656888T3 (da) * 1992-08-25 1998-02-09 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
EP1001019A1 (en) 1993-10-27 2000-05-17 Athena Neurosciences, Inc. Transgenic animals harboring APP Allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
WO1996001788A2 (en) * 1994-07-07 1996-01-25 Pharm-Eco Laboratories, Incorporated Amino acid-derived diaminopropanols
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
JPH09124629A (ja) * 1995-10-26 1997-05-13 Kissei Pharmaceut Co Ltd カルバミン酸テトラヒドロフリルエステル誘導体の製造方法
DK0948630T3 (da) 1996-11-20 2008-08-11 Oklahoma Med Res Found Kloning og karakterisering af napsin, en asparaginprotease
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
KR100768381B1 (ko) 1998-09-24 2007-10-18 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
AU4000900A (en) 1999-02-10 2000-08-29 Elan Pharmaceuticals, Inc. Beta-secretase enzyme compositions and methods
SI1159278T1 (sl) * 1999-02-12 2006-06-30 Vertex Pharma Inhibitorji aspartil proteaze
CA2376420A1 (en) 1999-06-15 2000-12-21 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
CA2397786A1 (en) 1999-09-23 2001-04-05 Pharmacia & Upjohn Company Alzheimer's disease secretase, app substrates therefor, and uses therefor
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
DE60116313T2 (de) * 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
US6696488B2 (en) * 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
BR0210122A (pt) * 2001-06-01 2004-06-15 Elan Pharm Inc Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
KR20040063110A (ko) * 2001-07-11 2004-07-12 엘란 파마슈티칼스, 인크. Ｎ-(3-아미노-2-히드록시-프로필) 치환된 알킬아미드 화합물
OA12846A (en) * 2001-11-08 2006-09-15 Elan Pharm Inc N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives.
US7312360B2 (en) * 2001-12-06 2007-12-25 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
CN101090883A (zh) * 2002-02-27 2007-12-19 艾伦药物公司 取代羟基乙胺
DE60315023T2 (de) * 2002-04-26 2008-04-03 Gilead Sciences, Inc., Foster City Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
BR0312439A (pt) * 2002-06-20 2005-05-10 Pharmacia & Upjohn Co Llc Processo para preparação de derivados de ácido 5-(1,3-oxazol-2-il)benzóico
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
WO2004022523A2 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
WO2004043916A1 (en) * 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
KR100793095B1 (ko) * 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7291744B2 (en) * 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
AU2003293155A1 (en) 2004-06-23
CA2507484A1 (en) 2004-06-17
WO2004050609A1 (en) 2004-06-17
EP1565428A1 (en) 2005-08-24
US7351738B2 (en) 2008-04-01
PA8589701A1 (es) 2004-11-26
MXPA05005649A (es) 2005-08-16
AR043062A1 (es) 2005-07-13
PE20040762A1 (es) 2004-11-06
AU2003293155A8 (en) 2004-06-23
BR0316629A (pt) 2005-10-11
DOP2003000765A (es) 2004-05-31
WO2004050609A8 (en) 2005-07-21
JP2006508166A (ja) 2006-03-09
UY28101A1 (es) 2004-06-30
US20040209925A1 (en) 2004-10-21
US20080306136A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
MXPA04006575A (es) Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
MXPA04003245A (es) Hidroxipropilaminas.
AP2004002952A0 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds.
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
WO2003103653A8 (en) METHODS OF TREATING ALZHEIMER'S DISEASE WITH ALKANOIC ARYL ACID AMIDES
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
WO2004029019A3 (en) Compounds for the treatment of alzheimer’s disease
WO2002094768A3 (en) Aza hydroxylated ethyl amine compounds
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
WO2005042472A3 (en) Hydroxypropyl amides for the treatment of alzheimer’s disease
WO2004037179A3 (en) Substituted peptides useful in the treatment of alzheimer’s disease